A prospective study by Ros et al. found that a high plasmatic allele fraction (AF) of BRAF was associated with worse PFS and OS as compared to low AF in patients with BRAF-mutated CRC treated with BRAF and anti-EGFR inhibitors. This evidence concerns the gene BRAF and colorectal carcinoma.